Book Review: Transhumanist Dreams and Dystopian Nightmares
By John Galloway,
BioNews
| 03. 11. 2013
Perhaps fortuitously, I started to read
Maxwell Mehlman's
book at the same time as
Roy Porter's 'A Short History of Madness'. It was then difficult not to muse on what
Jonathan Swift might have made of 'transhumanising scientists'. His satirising of scientists 'infected with lunacy' in the eighteenth century provides a hard to avoid parallel with Mehlman's very much not satirical account of biologists of the twentieth century.
Every school child now knows that molecular genetics is set to transform the world as we know it. Although exactly who 'we' are, is not specified; nor are we always told whether the transformation will be for good or ill. We can be reasonably certain though that most of the world's existing population will be dead before genetics' claims for medicine have any effect on them.
Read more...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Justin McCurry, The Guardian | 04.01.2024
A Chinese scientist who was imprisoned for his role in creating the world’s first genetically edited babies says he has returned to his laboratory to work on the treatment of Alzheimer’s and other genetic diseases.
In an interview with a...